<DOC>
	<DOCNO>NCT00967187</DOCNO>
	<brief_summary>To evaluate antiretroviral activity safety 200 mg BID 300 mg BID dose MPC-4326 administer monotherapy 14 day HIV-1 positive patient . Patients initial treatment response option continue MPC-4326 combination Optimized Backround Regimen maximum 72 week .</brief_summary>
	<brief_title>Safety Efficacy Study MPC-4326 Treatment Patients With HIV-1 Infection .</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Be least 18 year age time screen . Have HIV1infection . Have CD4+lymphocyte countâ‰¥100 cells/mm3 Have screen plasma HIV1 RNA value , measure Roche Amplicor assay , 2,000 500,000 copies/mL ( inclusive ) . Be free acute infection serious medical illness within 14 day prior study entry . Current opportunistic infection characteristic AIDS ( Category C accord CDC Classification System HIV1 Infection , 1993 Revised Version , Appendix A ) diagnose within 30 day poorly control . Patients systolic blood pressure &lt; 90 mmHg &gt; 140 mmHg diastolic blood pressure &lt; 60 mmHg &gt; 90 mmHg . A history seizure ( exclude pediatric febrile seizure ) current administration prophylactic antiseizure medication . A history cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) . Patients follow laboratory parameter within 30 day prior first dose study drug : Hemoglobin &lt; 10.0 g/dL men &lt; 9.0 g/dL woman Neutrophil count &lt; 1000/mm3 Platelet count &lt; 50,000/mm3 AST ALT &gt; 2.5 time upper limit normal ( patient positive HBV surface antigen HCV antibody test screening must AST ALT 1.5 time upper limit normal )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>